Ogletree Deakins and KPMG Law Join Forces in a New Alliance
Ogletree Deakins and KPMG Law in Germany1 are forming a global alliance to provide businesses with global workforce solutions. This alliance will be instrumental in expanding immigration and employment law reach for both organizations and will enable KPMG firms outside of the US2 to bring the US capability and services of Ogletree Deakins to their clients around the world.
The alliance is in response to growing client demand for a technology-powered, globally unified approach to business challenges faced in the areas of immigration and global mobility, labor and employment, and the associated tax, compensation, and benefits issues. This non-exclusive alliance with Ogletree Deakins does not include KPMG in the US or entities that it owns or controls, which do not provide legal services3.
“As businesses expand and look to shore up recovery in the post-pandemic world, there is increasing pressure for multinational organizations seeking to get the right people in the right places at the right time, and in compliance with the requirements of any given jurisdiction,” said Thomas Wolf, Head of Global Immigration Services for the KPMG organization. “Ogletree Deakins’ labor, employment and immigration experience in the United States is a perfect fit for KPMG’s organization of firms as we expand our global legal services practice4 and our global mobility services offerings around the world. We are excited to join forces with Ogletree Deakins to offer clients even deeper global coverage for their pressing employment and immigration legal matters.”
Both Ogletree Deakins and KPMG Law in Germany are leaders in utilizing technology and innovation to enhance client service, including in the areas of artificial intelligence, data analytics and knowledge management. By combining the strengths of both organizations, this new alliance will provide clients with an increased breadth of technology solutions. KPMG Law in Germany is part of the broader KPMG Law / Global Legal Services network across KPMG firms, with 2,800 lawyers in 81 jurisdictions.
“Ogletree Deakins is an international labor and employment firm and has established an extensive network of lawyers practicing in 53 offices across North America and in Europe to meet our clients’ needs. Our alliance with KPMG Law in Germany will benefit clients by complementing our US labor, employment and immigration offerings with ‘end-to-end’ workplace solutions—including tax, compensation, global immigration, and related advisory and consulting services, over a truly global footprint. Our firm shares a vision with the KPMG network for client service, innovation and cutting-edge technology solutions, and we are already working together on a next generation mobility services platform,” said Matt Keen, managing shareholder of Ogletree Deakins.
About Ogletree Deakins
Ogletree Deakins is one of the largest US labor and employment law firms representing management in all types of employment-related legal matters. Premier client service, as outlined in the firm’s Client Pledge, is one of the firm’s top priorities and a cornerstone of its core values. U.S. News – Best Lawyers® “Best Law Firms” has named Ogletree Deakins a “Law Firm of the Year” for 10 consecutive years. In 2021, the publication named Ogletree Deakins its “Law Firm of the Year” in the Litigation – Labor & Employment category. Ogletree Deakins has more than 900 attorneys located in 53 offices across the United States and in Europe, Canada, and Mexico. The firm represents a diverse range of clients, from small businesses to Fortune 50 companies. More: ogletree.com.
About KPMG International
KPMG is a global organization of independent professional services firms providing Audit, Tax and Advisory services. We operate in 146 countries and territories and in FY20 had close to 227,000 people working in member firms around the world. Each KPMG firm is a legally distinct and separate entity and describes itself as such. KPMG International Limited is a private English company limited by guarantee. KPMG International Limited and its related entities do not provide services to clients. More: kpmg.com
_______________________________
1 The agreement will be initially signed by KPMG Law Rechtsanwaltsgesellschaft mbH (“KPMG Law in Germany”), which is associated with KPMG AG Wirtschaftsprüfungsgesellschaft, the German member firm of the KPMG network of independent member firms affiliated with KPMG International Cooperative, a Swiss entity. Other non-US member firms are expected to join this non-exclusive alliance over the next several months.
2 KPMG Law in Germany was established in 2007 and is an independent corporate law firm associated with KPMG AG Wirtschaftsprüfungsgesellschaft and affiliated with the KPMG International Cooperative. This non-exclusive alliance with Ogletree Deakins does not include the KPMG US member firm or entities that it owns, or controls, which do not provide legal services. For cases where KPMG in the US clients require immigration and/or employment and labor law services, Ogletree Deakins may contract with these clients separately.
3 For cases where KPMG US clients require immigration and/or employment and labor law services, Ogletree Deakins would contract with these clients separately.
4 Certain member firms of the KPMG global organization, including KPMG in the US, do not provide legal services. For the purpose of this press release any commentary will be on general concepts only and is not in any way intended as legal advice or views on laws of any jurisdiction.
Some or all of the services described herein may not be permissible for KPMG audit clients and their affiliates and related entities.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210509005026/en/
Contact information
Ryan King
Ogletree Deakins
(404) 870-1742
ryan.king@ogletree.com
Lauren Ruiz
Ogletree Deakins
(404) 260-0645
lauren.ruiz@ogletree.com
Amy Diaz
KPMG International
(416) 777-3042
amydiaz@kpmg.ca
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 19:03:00 EEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 18:43:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 18:22:00 EEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/ Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 15:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new
MEDIA ALERT: Wolters Kluwer expert comments on European Parliament vote to pass amendment implementing Basel III reforms26.4.2024 15:00:00 EEST | Press release
The European financial landscape saw a milestone event this week, as the EU Parliament passed the Amendment to Regulation (EU) No 575/2013, implementing the Basel III finalization within Europe. This monumental step forward comes with the adoption of the Capital Requirements Regulation (CRR3) amendments, which are part of a broader legislative package, including amendments to Directive 2013/36/EU, known as the Capital Requirements Directive or CRD. Jeroen Van Doorsselaere, Vice President of Global Product & Platform Management, Wolters Kluwer FRR, said: “The adoption of the Capital Requirements Regulation (CRR3) amendments represents a landmark change for the banking industry, designed to strengthen the framework for risk-based capital requirements and address ESG risks. “This is a major overhaul of the capital requirements framework, impacting various aspects, including credit risk, operational risk, market risk, and the capital floor. Whereas other significant jurisdictions, includin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom